Journal
TRENDS IN MOLECULAR MEDICINE
Volume 26, Issue 7, Pages 630-638Publisher
CELL PRESS
DOI: 10.1016/j.molmed.2020.03.005
Keywords
-
Funding
- Robert and Arlene Kogod Professorship
- National Institutes of Health [P01 AG062413, P01 AG004875, R01 AG048792, R37 AG 013925, R33 061456]
- Connor Group
- Robert and Theresa Ryan Foundation
- Noaber Foundation
- Ted Nash Foundation
Ask authors/readers for more resources
Cellular senescence is a primary aging process and tumor suppressive mechanism characterized by irreversible growth arrest, apoptosis resistance, production of a senescence-associated secretory phenotype (SASP), mitochondrial dysfunction, and alterations in DNA and chromatin. In preclinical aging models, accumulation of senescent cells is associated with multiple chronic diseases and disorders, geriatric syndromes, multimorbidity, and accelerated aging phenotypes. In animals, genetic and pharmacologic reduction of senescent cell burden results in the prevention, delay, and/or alleviation of a variety of aging-related diseases and sequelae. Early clinical trials have thus far focused on safety and target engagement of senolytic agents that clear senescent cells. We hypothesize that these pharmacologic interventions may have transformative effects on geriatric medicine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available